About: Coronavirus Disease 2019 and Cardiovascular System: A Narrative Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coronavirus Disease 2019 and Cardiovascular System: A Narrative Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coronavirus Disease 2019 and Cardiovascular System: A Narrative Review
Creator	Kurniawan, Kurniawan, Andree Damay, Vika Kwenandar, Felix Tanaka, Michael Banten, Karawaci Hariyanto, Ivan Japar, Karunia Lugito, Hardjito Pd, Sp Pratama, Nata Village, Lippo
Source	Elsevier; Medline; PMC
abstract	At the end of 2019, a viral pneumonia disease called coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerged in Wuhan, China. This novel disease rapidly spread at an alarming rate that as a result, it has now been declared pandemic by the World Health Organization. Although this infective disease is mostly characterized by respiratory tract symptoms, increasing numbers of evidence had shown considerable amounts of patients with cardiovascular involvements and these were associated with higher mortality among COVID-19 patients. Cardiac involvement as a possible late phenomenon of the viral respiratory infection is an issue that should be anticipated in patients with COVID-19. Cardiovascular manifestation in COVID-19 patients include myocardial injury (MI), arrhythmias, cardiac arrests, heart failure and coagulation abnormality, ranging from 7.2% up to 33%. The mechanism of cardiac involvement in COVID-19 patients involves direct injury to myocardial cells mediated by angiotensin-converting enzyme 2 (ACE2) receptors as suggested by some studies, while the other studies suggest that systemic inflammation causing indirect myocyte injury may also play a role. Combination of proper triage, close monitoring, and avoidance of some drugs that have cardiovascular toxicity are important in the management of cardiovascular system involvement in COVID-19 patients. The involvement of the cardiovascular system in COVID-19 patients is prevalent, variable, and debilitating. Therefore, it requires our attention and comprehensive management.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1016/j.ijcha.2020.100557
bibo:pmid	32550259
has license	no-cc
sha1sum (hex)	f573fd512b08380571649cee4d2c69b4386f1780
schema:url	https://doi.org/10.1016/j.ijcha.2020.100557
resource representing a document's title	Coronavirus Disease 2019 and Cardiovascular System: A Narrative Review
has PubMed Central identifier	PMC7266760
has PubMed identifier	32550259
schema:publication	Int J Cardiol Heart Vasc
resource representing a document's body	covid:f573fd512b08380571649cee4d2c69b4386f1780#body_text
is schema:about of	named entity 'Review' named entity 'Coronavirus' named entity 'Cardiovascular' named entity 'Narrative Review' named entity 'Troponin' named entity 'oxygen' named entity 'vascular endothelium' named entity 'Coronary heart disease' named entity 'Reperfusion therapy' named entity 'respiratory failure' named entity 'critically ill' named entity 'clinical presentation' named entity 'COVID' named entity 'myocardium' named entity 'triage' named entity 'China' named entity 'percutaneous coronary intervention' named entity 'reperfusion therapy' named entity 'COVID' named entity 'cardiovascular disorders' named entity 'myocardial infarction' named entity 'virally induced' named entity 'troponin' named entity 'angiotensin-converting enzyme 2' named entity 'infarct' named entity 'SARS-CoV-2' named entity 'triage' named entity 'ACE2' named entity 'viral infection' named entity 'TnT' named entity 'cardiovascular' named entity 'acute myocardial injury' named entity 'COVID' named entity 'unfractionated heparin' named entity 'Italy' named entity 'COVID-19' named entity 'Tao Guo' named entity 'COVID-19' named entity 'metabolic' named entity 'experimental studies' named entity 'myocardial inflammation' named entity 'lung edema' named entity 'genome' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'COVID' named entity 'cardiovascular' named entity 'viral infection' named entity 'risk factors' named entity 'CVD' named entity 'cardiac reserve' named entity 'CVD' named entity 'COVID' named entity 'SARS-CoV' named entity 'arrhythmia' named entity 'SARS-CoV-2' named entity 'receptor' named entity 'thrombogenesis' named entity 'TnT' named entity 'aspirin' named entity 'coronary artery disease' named entity 'infection' named entity 'genome' named entity 'comorbidities' named entity 'intensive care' named entity 'cardiomyocytes' named entity 'mortality rate' named entity 'risk factors' named entity 'antivirals' named entity 'Coagulation abnormalities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software